Dernières nouvelles pour Carvana (NYSE:CVNA) Stock

CARVANA CO

Carvana

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.

Carvana Co

WIIM

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings shares are trading lower after the company announced a public offering.

- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older -
- PTC will host a conference call on Monday, July 28th at 5:00 pm ET -
WARREN, N.J., July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE&#x2122; (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU.
&nbsp;
The FDA approval is based on the evidence of significant efficacy and safety from the&nbsp; Phase 3 APHENITY trial as well as durability of treatment effect in the APHENITY long-term extension study. &nbsp;&nbsp;
SEPHIENCE was recently granted marketing authorization by the European Commission. Review of approval applications is ongoing in several other countries including Japan and Brazil.
&nbsp;

Biotech

News

General

PTCT

PTC Therapeutics Gains FDA Approval For SEPHIENCE To Treat All Ages With Sepiapterin-Responsive PKU; Will Host A Conference Call On Monday, July 28th At 5:00 pm ET

Guidance

Piedmont Realty Trust Affirms FY2025 FFO Guidance of $1.38-$1.44 vs $1.41 Est

RMBS

Rambus shares are trading higher after the company provided Q3 sales guidance.

Celestica shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY25 guidance, and issued Q3 guidance above estimates.

<ul>
<li>Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus</li>
<li>Bain Capital leads $300 million financing commitment</li>
</ul>
Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>, "BMS"))) and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.
The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively.
The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines.

Contracts

Bristol Myers And Bain Capital Launch $300M Autoimmune Biotech With 5 In-Licensed Immunology Assets, Including Late-Stage Lupus Drug

Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) sees Q3 sales of $166.000 million-$184.000 million vs $174.332 million analyst estimate.

Rambus Sees Q3 Sales $166.000M-$184.000M vs $174.332M Est

Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) sees Q3 sales of $167.000 million-$185.000 million vs $174.332 million analyst estimate.

Rambus Sees Q3 Sales $167.000M-$185.000M vs $174.332M Est

Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.57 by 16.73 percent. This is a 57.07 percent increase over earnings of $1.91 per share from the same period last year. The company reported quarterly sales of $62.70 million which beat the analyst consensus estimate of $56.50 million by 10.96 percent. This is a 56.64 percent increase over sales of $40.03 million the same period last year.

Earnings

Earnings Beats

Northeast Bank Q4 EPS $3.00 Beats $2.57 Estimate, Sales $62.70M Beat $56.50M Estimate

Crane shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) by 2.78 percent. This is a 82.41 percent increase over losses of $(1.99) per share from the same period last year. The company reported quarterly sales of $852.282 thousand which beat the analyst consensus estimate of $366.667 thousand by 132.44 percent. This is a 183.15 percent increase over sales of $301.000 thousand the same period last year.

GOVX

Geovax Labs Q2 EPS $(0.35) Beats $(0.36) Estimate, Sales $852.282K Beat $366.667K Estimate

Action positions Company for future inclusion in the Russell Family of Indices
flyExclusive, Inc. (NYSEAMERICAN: FLYX) ("flyExclusive" or the "Company"), a leading provider of premium private jet experiences, today announced it has executed a waiver letter (the "Waiver Letter"), effective immediately, to waive the lock-up of 5,625,000 shares of the Company's Class A common stock and warrants to purchase 4,333,333 shares of the Company's Class A common stock owned by EG Sponsor LLC ("EG Sponsor") and its affiliates (excluding those shares attributable to the former independent directors of EG Acquisition Corp., which were only subject to a one-year lock-up that has now expired). The lock-up has already been in effect for over 18 months since the closing of the Company's merger with EG Acquisition Corp. on December 27, 2023, and was set to expire on December 27, 2026.
The Company notified EG of its desire to remove the lock-up on EG Sponsor's Class A Common stock and warrants, to which EG Sponsor agreed, as the Company believes it positions flyExclusive to be included in the Russell Indices, which is expected to benefit its shareholders through increased volume and liquidity and support the Company's capital raising efforts.

FLYX

flyExclusive Waives Lock-Up On 5.6M Shares And 4.3M Warrants To Position For Inclusion In Russell Indices

Equifax And Qlarifi Partner To Conduct Joint Study On Impact Of BNPL Reporting On Credit Risk Assessments And Fraud Prevention

Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) raises FY2025 Adj EPS guidance from $18.45-$19.95 to $20.00-$21.00 vs $19.68 analyst estimate. Narrows FY2025 sales outlook from $17.020 billion-$17.364 billion to $17.096 billion-$17.312 billion vs $17.136 billion estimate.

Universal Health Services Raises FY2025 Adj EPS Guidance from $18.45-$19.95 to $20.00-$21.00 vs $19.68 Est; Narrows FY2025 Sales Guidance from $17.020B-$17.364B to $17.096B-$17.312B vs $17.136B Est

Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.33 by 19.82 percent. This is a 35.9 percent increase over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $300.724 million which beat the analyst consensus estimate of $296.795 million by 1.32 percent. This is a 0.03 percent increase over sales of $300.632 million the same period last year.

ABCB

Ameris Q2 Adj. EPS $1.59 Beats $1.33 Estimate, Sales $300.724M Beat $296.795M Estimate

Earnings Misses

Piedmont Office Realty Q2 FFO $0.36 Beats $0.35 Estimate, Sales $140.292M Miss $142.000M Estimate

GBank Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBFH#NASDAQ">GBFH</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.39 by 15.38 percent. This is a 8.33 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $17.772 million which beat the analyst consensus estimate of $12.800 million by 38.84 percent. This is a 14.55 percent increase over sales of $15.514 million the same period last year.

GBFH

GBank Financial Holdings Q2 EPS $0.33 Misses $0.39 Estimate, Sales $17.772M Beat $12.800M Estimate

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) reported quarterly earnings of $5.35 per share which beat the analyst consensus estimate of $4.92 by 8.74 percent. This is a 24.13 percent increase over earnings of $4.31 per share from the same period last year. The company reported quarterly sales of $4.283 billion which beat the analyst consensus estimate of $4.239 billion by 1.04 percent. This is a 9.60 percent increase over sales of $3.908 billion the same period last year.

Universal Health Servs Q2 Adj. EPS $5.35 Beats $4.92 Estimate, Sales $4.283B Beat $4.239B Estimate

SRPT

Trading Halt: Halted at 4:18:58 p.m. ET - Trading Halt: Halt News Pending

Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) raises FY2025 Adj EPS guidance from $5.30-$5.60 to $5.50-$5.80 vs $5.54 analyst estimate..

Crane Raises FY2025 Adj EPS Guidance from $5.30-$5.60 to $5.50-$5.80 vs $5.54 Est; Sales for 2025 FY is expected to up by 6.5% YoY

Press Releases

Carvana and PPA Tour Build on Successful Title Sponsorship with New Multi-Year Partnership

Carvana Unveils Jimmie Johnson's 700th Start Tribute Paint Scheme for Coca-Cola 600, Honoring NASCAR Legacy and Fallen Heroes

Carvana Brings Inspection and Reconditioning Center Capabilities to ADESA Nashville

Carvana to Present at Upcoming William Blair 45th Annual Growth Stock Conference

Carvana Expands Same-Day Delivery to Denver Area

Markets

Defiance Launches CVNX: The First 2X Long ETF for Carvana Co.

Jon Hamm and Carvana Launch National Campaign Highlighting the Simpler Way to Sell Your Car

Carvana to Report Second Quarter 2025 Results and Host Quarterly Conference Call on July 30

Small-Cap Stocks Show Signs Of Life As Market Rally Broadens

Carvana Brings Inspection and Reconditioning Center Capabilities to ADESA Seattle

CVNA

SMCI

Advance Auto Parts

Asbury Automotive Group

AutoNation

ARKO

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

AutoZone

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Carvana

Actualités

Dernières nouvelles pour Carvana (NYSE:CVNA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL